The estimated Net Worth of J Tyler Martin is at least $2.42 million dollars as of 16 November 2012. J Martin owns over 35,759 units of Dynavax Technologies stock worth over $2,422,991 and over the last 15 years J sold DVAX stock worth over $0.
J has made over 1 trades of the Dynavax Technologies stock since 2012, according to the Form 4 filled with the SEC. Most recently J exercised 35,759 units of DVAX stock worth $56,499 on 16 November 2012.
The largest trade J's ever made was exercising 35,759 units of Dynavax Technologies stock on 16 November 2012 worth over $56,499. On average, J trades about 5,108 units every 0 days since 2010. As of 16 November 2012 J still owns at least 222,089 units of Dynavax Technologies stock.
You can see the complete history of J Martin stock trades at the bottom of the page.
J's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY, CA, 94710.
Over the last 21 years, insiders at Dynavax Technologies have traded over $196,839,440 worth of Dynavax Technologies stock and bought 2,463,112 units worth $11,318,051 . The most active insiders traders include Andrew A. F. Hack, Partners L P/Ilbiotechnolog... et James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $1,533,390. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth $43,127.
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Dynavax Technologies executives and other stock owners filed with the SEC include: